| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7781449 | ALLERGAN | Trospium chloride treatment method |
Nov, 2024
(6 months from now) | |
| US7781448 | ALLERGAN | Once daily dosage forms of trospium |
Nov, 2024
(6 months from now) | |
| US7759359 | ALLERGAN | Method of treating bladder dysfunction with once-a-day trospium salt formulation |
Nov, 2024
(6 months from now) | |
| US7763635 | ALLERGAN | Once daily dosage forms of trospium |
Nov, 2024
(6 months from now) | |
| US7410978 | ALLERGAN | Once daily dosage forms of trospium |
Feb, 2025
(8 months from now) | |
Sanctura Xr is owned by Allergan.
Sanctura Xr contains Trospium Chloride.
Sanctura Xr has a total of 5 drug patents out of which 0 drug patents have expired.
Sanctura Xr was authorised for market use on 03 August, 2007.
Sanctura Xr is available in capsule, extended release;oral dosage forms.
Sanctura Xr can be used as method of treating bladder dysfunction with once a day trospium salt formulation.
The generics of Sanctura Xr are possible to be released after 01 February, 2025.
Drugs and Companies using TROSPIUM CHLORIDE ingredient
Market Authorisation Date: 03 August, 2007
Treatment: Method of treating bladder dysfunction with once a day trospium salt formulation
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
SANCTURA XR family patents
